Review

QC and QA in pharmaceuticals: An industrial perspective

Shiful Islam 1,*

1 Department of Biotechnology, Faculty of Natural Science, Norwegian University of Science and Technology, Trondheim 7491, Norway.

* Correspondence: saifparvez95@gmail.com (S.I.)

Citation: Islam, S. QC and QA in pharmaceuticals: An industrial perspective. Glob. Jour. Bas. Sci. 2025, 1(11). 1-7.

Received: June 21, 2025

Revised: August 11, 2025

Accepted: September 02, 2025

Published: September 03, 2025

doi: 10.63454/jbs20000056

ISSN: 3049-3315

Volume 1; Issue 11

Download PDF file

Abstract: Quality Control (QC) and Quality Assurance (QA) represent the cornerstone of the pharmaceutical industry, serving as critical mechanisms to guarantee that medicinal products are consistently safe, effective, and of the highest quality. As pharmaceutical manufacturing becomes increasingly globalized and subject to heightened regulatory oversight, the establishment of robust QC and QA systems has become indispensable for compliance with international standards, particularly Good Manufacturing Practices (GMP). QC focuses on the systematic testing and verification of raw materials, intermediates, and finished products to ensure they meet predefined specifications, while QA encompasses the broader framework of policies, procedures, and preventive measures that safeguard product integrity throughout the entire production lifecycle. This review provides an industrial perspective on the principles, functions, and integration of QC and QA in modern pharmaceutical manufacturing. It highlights the critical role of regulatory frameworks such as those established by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO), which collectively shape global compliance requirements. Operational responsibilities, including risk management, deviation handling, and corrective and preventive actions (CAPA), are examined to illustrate how QC and QA teams collaborate to maintain product reliability. The importance of documentation systems—covering batch records, standard operating procedures (SOPs), and audit trails—is emphasized as a foundation for transparency, traceability, and regulatory inspections. Furthermore, emerging trends such as the adoption of digital technologies, automation, and data-driven analytics are discussed as transformative tools that enhance efficiency, reduce human error, and strengthen patient safety. The integration of Quality by Design (QbD) principles and continuous improvement strategies further underscores the industry’s commitment to proactive quality management. By synthesizing these elements, the review underscores how QC and QA not only ensure regulatory compliance but also foster innovation, trust, and sustainability in pharmaceutical manufacturing, ultimately safeguarding public health.

Keywords: Quality Control; Quality Assurance; Pharmaceuticals; GMP; Regulatory Compliance

1. Introduction

The pharmaceutical industry plays a critical role in safeguarding public health by developing and supplying medicines that must adhere to rigorous standards of quality, safety, and efficacy. Unlike many other consumer products, pharmaceuticals directly influence human health outcomes, and therefore any compromise in drug quality can lead to serious adverse effects, therapeutic failure, regulatory sanctions, and erosion of public trust in healthcare systems [1-5]. 

To mitigate these risks, pharmaceutical manufacturing is governed by comprehensive Quality Control (QC) and Quality Assurance (QA) systems, which together ensure that every stage of production—from raw material procurement to final product release—meets established specifications and regulatory requirements [2-4]. QC is primarily concerned with analytical testing, validation, and verification of raw materials, intermediates, and finished products, ensuring that they conform to predefined standards before reaching patients [3]. QA, on the other hand, represents a proactive and systemic framework that integrates policies, procedures, and preventive measures to guarantee that quality is embedded throughout the product lifecycle, including design, development, manufacturing, packaging, and distribution [4]. 

The integration of QC and QA forms the backbone of pharmaceutical quality systems, serving as a dual safeguard against variability, contamination, and non-compliance. Regulatory authorities such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and World Health Organization (WHO) mandate adherence to Good Manufacturing Practices (GMP), which explicitly require companies to establish robust QC and QA structures [5-10]. These systems not only ensure compliance but also promote operational excellence, continuous improvement, and patient safety, thereby reinforcing the credibility of pharmaceutical manufacturers in global markets [11-15]. 

In recent years, the importance of QC and QA has grown further due to globalized supply chains, advanced biopharmaceutical technologies, and increasing regulatory scrutiny. As a result, pharmaceutical companies are investing in digitalization, automation, and data-driven quality systems to strengthen traceability, reduce human error, and enhance efficiency [16-21]. Thus, QC and QA are not merely regulatory obligations but strategic imperatives that underpin the industry’s mission to deliver safe and effective medicines to patients worldwide.

2. Overview of quality systems in pharmaceuticals 

Pharmaceutical quality systems are comprehensive and structured frameworks that ensure medicinal products consistently meet the stringent standards of safety, efficacy, and quality required by both patients and regulatory authorities. Unlike traditional approaches that relied heavily on end-product testing, modern quality systems adopt a holistic and proactive model that integrates Quality Control (QC), Quality Assurance (QA), risk management, and continual improvement into every stage of the product lifecycle [1-10]. This paradigm shift reflects the industry’s recognition that quality must be designed into processes rather than inspected into products.

The International Council for Harmonisation (ICH) guideline Q10 provides a globally recognized model for pharmaceutical quality systems. It emphasizes lifecycle management, harmonization across regulatory jurisdictions, and the establishment of a culture  of quality within organizations. ICH Q10 builds upon earlier frameworks such as Good Manufacturing Practices (GMP) and incorporates modern concepts like Quality by Design (QbD) and risk-based approaches, ensuring that pharmaceutical companies can adapt to evolving scientific and regulatory landscapes [11-21].

The primary objectives of pharmaceutical quality systems are multifaceted. First, they ensure strict compliance with regulatory requirements, which is essential for maintaining market authorization and avoiding sanctions. Second, they prioritize the prevention of defects rather than reliance on detection alone, thereby reducing the likelihood of costly recalls and safeguarding patient health. Third, they promote continuous monitoring and improvement of processes, enabling manufacturers to identify inefficiencies and implement corrective actions. Finally, they guarantee data integrity and traceability, ensuring that all records are reliable, transparent, and auditable—a critical requirement in an era of digitalization and globalized supply chains [3-11].

By embedding these principles, pharmaceutical companies can minimize variability in production, reduce risks of contamination, and strengthen patient confidence in drug safety. A robust quality system also enhances organizational resilience, allowing manufacturers to respond effectively to regulatory inspections, market demands, and technological innovations. Moreover, quality systems serve as a foundation for operational excellence, enabling companies to integrate advanced technologies such as automation, artificial intelligence, and real-time monitoring into their processes. This adaptability ensures that pharmaceutical manufacturers remain competitive while upholding their ethical responsibility to deliver safe and effective medicines [21-33].

3. Quality control (QC) in pharmaceuticals

Quality control (QC) in the pharmaceutical industry refers to the set of operational techniques and activities designed to ensure that products meet predefined quality requirements (Figure 1). It is a critical component of the overall pharmaceutical quality system, focusing on the verification and validation of raw materials, intermediates, packaging components, and finished products. QC ensures that every batch of medicine released to the market complies with pharmacopeial standards and regulatory specifications, thereby safeguarding patient health and maintaining industry credibility. Unlike Quality assurance (QA), which emphasizes prevention and system-wide measures, QC is primarily concerned with detection and confirmation through rigorous testing and monitoring [1-5,34-50].

Figure 1. QC and QA in pharmaceuticals from industrial point of view.

3.1 Functions of QC

The functions of Quality Control (QC) are broad and encompass multiple stages of pharmaceutical manufacturing, from incoming raw materials to finished product evaluation and post-manufacturing monitoring. QC ensures that all materials, processes, and products comply with predefined quality standards, pharmacopeial specifications, and regulatory requirements [7-15]. By applying scientifically validated analytical methods and systematic monitoring, QC plays a crucial role in safeguarding product quality, consistency, and patient safety. 

3.1.1. Testing of raw materials, packaging materials, and intermediates: Before the initiation of manufacturing, QC is responsible for the sampling and testing of raw materials, including active pharmaceutical ingredients (APIs) and excipients, to verify their identity, purity, strength, and compliance with approved specifications. Packaging materials such as containers, closures, labels, and blister packs are also evaluated to ensure they are suitable, safe, and compatible with the product, thereby preventing contamination or interaction. In addition, intermediates generated during various stages of manufacturing are tested to confirm that critical quality attributes are being met and that the process is progressing as intended. This comprehensive testing helps prevent the use of substandard materials and reduces the risk of quality failures in later stages.

3.1.2. In-process quality checks: QC teams perform in-process quality control tests during manufacturing to monitor critical parameters in real time and detect deviations at an early stage. These checks may include assessments of pH, viscosity, blend uniformity, tablet weight variation, hardness, friability, and fill volume, depending on the dosage form. In-process monitoring allows immediate corrective actions to be taken if results fall outside acceptable limits, thereby minimizing waste, preventing batch failure, and ensuring consistent product quality throughout the manufacturing process.

3.1.3. Finished product analysis: Upon completion of manufacturing and packaging, finished pharmaceutical products undergo comprehensive laboratory testing to confirm compliance with pharmacopeial and regulatory specifications. These tests typically include evaluation of assay, content uniformity, dissolution, impurity profile, sterility, endotoxin levels, and physical characteristics. Finished product analysis serves as a final verification step before batch release and is essential for demonstrating product quality, safety, and efficacy to regulatory authorities and ensuring suitability for patient use.

3.1.4. Stability studies: QC is responsible for conducting stability studies to establish the shelf life and appropriate storage conditions of pharmaceutical products. Stability testing evaluates the impact of environmental factors such as temperature, humidity, and light on product quality over time under both accelerated and long-term conditions. The data generated from these studies support expiration dating, packaging selection, and labeling instructions, ensuring that products remain safe and effective throughout their intended shelf life.

3.1.5. Environmental monitoring: In sterile and controlled manufacturing areas, QC performs routine environmental monitoring to assess air quality, water systems, surfaces, and personnel hygiene. This includes microbial monitoring, particulate counts, and evaluation of cleanroom conditions to detect potential sources of contamination. Effective environmental monitoring ensures compliance with GMP requirements, maintains aseptic conditions, and protects the quality of sensitive pharmaceutical products, particularly injectables and ophthalmic preparations [18,25,28,30,34,37].

Together, these Quality Control functions ensure that pharmaceutical products are consistently manufactured to be safe, effective, and reliable, while maintaining regulatory compliance and protecting public health.

3.2 Analytical techniques used in QC

Quality Control laboratories employ a broad range of analytical techniques to evaluate the identity, purity, strength, and safety of pharmaceutical products at various stages of manufacturing. These techniques are selected based on the nature of the dosage form, regulatory requirements, and pharmacopeial standards. All analytical methods used in QC must be scientifically validated to demonstrate accuracy, precision, specificity, linearity, and robustness [5,34-43]. In addition, analyses are performed using properly calibrated and qualified instruments under controlled laboratory conditions to ensure data integrity, reproducibility, and regulatory compliance.

3.2.1. High-Performance Liquid Chromatography (HPLC): High-Performance Liquid Chromatography (HPLC) is one of the most widely utilized analytical techniques in pharmaceutical QC due to its high sensitivity, precision, and versatility. HPLC is employed for the separation, identification, and quantification of active pharmaceutical ingredients (APIs), related substances, impurities, and degradation products in raw materials, intermediates, and finished dosage forms. It plays a critical role in stability studies, assay determination, and impurity profiling. The ability of HPLC to handle complex mixtures makes it indispensable for ensuring product quality and compliance with pharmacopeial and regulatory specifications.

3.2.2. Gas Chromatography (GC): Gas Chromatography (GC) is primarily used for the analysis of volatile and semi-volatile compounds, including residual solvents, process impurities, and certain excipients. This technique offers high sensitivity, selectivity, and resolution, allowing accurate quantification of trace-level contaminants. GC is essential for compliance with regulatory guidelines related to residual solvent limits, such as those outlined in ICH Q3C. Its application ensures that potentially harmful solvents are present within acceptable safety thresholds, thereby protecting patient health.

3.2.3. UV–Visible Spectroscopy: UV–Visible spectroscopy is a simple, rapid, and cost-effective analytical technique commonly used in routine QC analysis. It measures the absorbance of ultraviolet or visible light by a substance at specific wavelengths, enabling quantitative determination of drug concentration and assessment of purity. UV–Visible spectroscopy is frequently employed for assay testing, content uniformity, and dissolution sample analysis. Although less specific than chromatographic methods, it remains a valuable tool for routine quality monitoring and preliminary analysis.

3.2.4. Dissolution testing: Dissolution testing evaluates the rate and extent to which an active pharmaceutical ingredient is released from a solid dosage form into a dissolution medium under standardized conditions. This test simulates in vivo drug release and is critical for predicting bioavailability and therapeutic performance. Dissolution studies are essential for formulation development, batch-to-batch consistency, stability assessment, and regulatory approval. For generic products, dissolution testing plays a key role in demonstrating bioequivalence with the reference product.

3.2.5. Microbiological assays: Microbiological assays are used to detect microbial contamination and assess sterility in pharmaceutical products, particularly those intended for parenteral, ophthalmic, and inhalation use. These assays include sterility testing, microbial limit tests, endotoxin testing, and environmental microbial monitoring. Additionally, microbiological methods are employed to determine the potency of antibiotics and other antimicrobial agents. By ensuring microbiological safety and efficacy, these assays help protect patients from infection and ensure compliance with GMP and pharmacopeial standards.

By employing these techniques, QC laboratories generate reliable data that form the basis for product release decisions. The accuracy of these results depends on strict adherence to validated methods, proper calibration of instruments, and continuous training of laboratory personnel.

In essence, QC acts as the gatekeeper of pharmaceutical manufacturing, ensuring that only products meeting the highest standards reach patients. Its functions—ranging from raw material testing to environmental monitoring—are supported by advanced analytical techniques that provide precise and reproducible results. Without QC, pharmaceutical companies would risk releasing unsafe or ineffective medicines, undermining both patient safety and regulatory compliance.

4. Quality assurance (QA) in pharmaceuticals

Quality Assurance (QA) in the pharmaceutical industry is a comprehensive and system-oriented discipline that ensures medicinal products are consistently produced and controlled according to established quality standards. Unlike Quality Control (QC), which focuses on detecting defects through testing, QA emphasizes prevention, consistency, and compliance. It is proactive in nature, aiming to build quality into every stage of the product lifecycle—from raw material procurement and manufacturing to packaging, distribution, and post-market surveillance. QA provides the overarching framework that integrates policies, procedures, and monitoring systems to guarantee that pharmaceutical products are safe, effective, and reliable for patient use [34-50].

By adopting a preventive approach, QA reduces the likelihood of errors, deviations, and product recalls. It ensures that manufacturing processes are well-defined, validated, and continuously monitored, thereby minimizing variability and ensuring reproducibility. QA also plays a critical role in fostering a culture of quality within organizations, where employees at all levels understand their responsibilities in maintaining compliance and protecting patient safety.

Figure 2. Regulatory framework governing QC and QA, integration, and emerging trends.

4.1 Responsibilities of QA

The responsibilities of QA are extensive and cover multiple aspects of pharmaceutical operations. The responsibilities of Quality Assurance (QA) are extensive and encompass multiple aspects of pharmaceutical operations, ensuring that products are consistently manufactured and controlled in accordance with established quality standards. QA oversees compliance with Good Manufacturing Practices (GMP), regulatory requirements, and internal quality systems throughout the entire product lifecycle—from raw material procurement and manufacturing to packaging, storage, and distribution [44-50]. Key functions include documentation control, validation and qualification activities, deviation management, change control, risk assessment, internal audits, training programs, and batch record review. Additionally, QA plays a critical role in handling customer complaints, product recalls, and continuous quality improvement, thereby safeguarding product quality, patient safety, and regulatory compliance. 

4.1.1. Development and implementation of SOPs: Quality Assurance (QA) teams are responsible for the development, review, approval, and effective implementation of Standard Operating Procedures (SOPs) that define standardized methods for all critical activities involved in pharmaceutical manufacturing, quality control, validation, documentation, storage, and distribution. These SOPs provide clear, step-by-step instructions to ensure tasks are performed consistently and in compliance with Good Manufacturing Practices (GMP) and regulatory guidelines. Properly designed SOPs help minimize variability in operations, reduce the risk of human error, and enhance process reproducibility. QA also ensures version control, periodic review, and timely revision of SOPs to reflect regulatory updates,  process changes, or audit findings [51-64]. Furthermore, SOPs serve as essential reference documents during internal audits, regulatory inspections, and training programs, thereby supporting regulatory compliance, operational efficiency, and overall quality management within the organization.

4.1.2. Batch record review and release: Quality Assurance (QA) holds the ultimate authority for the review and release of batch manufacturing records (BMRs) and batch packaging records (BPRs). This review involves a thorough verification that all manufacturing, in-process control, testing, and packaging activities were performed strictly in accordance with approved Standard Operating Procedures (SOPs), master batch records, and applicable regulatory requirements. QA ensures that critical process parameters remained within predefined limits, all deviations were appropriately investigated and resolved, and required analytical results met established specifications [51-55]. Only after a comprehensive and satisfactory review does QA authorize batch release for distribution. This function acts as a critical quality gate, preventing the release of substandard or non-compliant products into the market and thereby safeguarding patient safety and product integrity (Figure 2). 

4.1.3. Validation of processes, equipment, and cleaning: QA oversees and approves validation activities to demonstrate that manufacturing processes consistently and reproducibly yield products meeting predetermined quality attributes. This includes process validation, equipment qualification (Installation Qualification, Operational Qualification, and Performance Qualification), and cleaning validation. Equipment qualification ensures that machinery operates as intended within defined operating ranges, while cleaning validation confirms the effective removal of residues, contaminants, and microorganisms to prevent cross-contamination between products. QA ensures that validation protocols are scientifically justified, executed according to regulatory guidelines, and supported by robust documentation, thereby maintaining product quality, consistency, and regulatory compliance. 

4.1.4. Change control management: Any change to raw materials, manufacturing processes, equipment, facilities, analytical methods, or documentation must be managed through a formal change control system under QA supervision. QA evaluates proposed changes to assess their potential impact on product quality, safety, efficacy, and regulatory status. This evaluation includes scientific justification, risk assessment, and, where necessary, validation or regulatory notification. QA ensures that no change is implemented without proper approval, documentation, and training, thereby maintaining a controlled state and preventing unintended consequences that could compromise product quality.

4.1.5. Deviation handling and CAPA implementation: QA is responsible for managing deviations from approved procedures, specifications, or expected results. This includes classification of deviations, investigation of root causes using systematic tools, and documentation of findings. Based on the investigation, QA ensures the implementation of appropriate Corrective and Preventive Actions (CAPA) to eliminate the root cause of the issue and prevent recurrence. Effectiveness checks are performed to confirm that CAPA measures achieve their intended outcomes. This structured deviation and CAPA management system supports continuous quality improvement and regulatory compliance.

4.1.6. Internal audits and regulatory inspections: QA conducts regular internal audits to evaluate compliance with Good Manufacturing Practices (GMP), internal quality systems, and regulatory requirements. These audits help identify gaps, assess operational effectiveness, and drive continuous improvement. QA also plays a central role in preparing organizations for regulatory inspections conducted by authorities such as the FDA, EMA, and WHO. During inspections, QA serves as the primary interface with inspectors, facilitates documentation review, addresses queries, and ensures timely and accurate responses. Effective audit and inspection management demonstrates the organization’s commitment to quality, transparency, and regulatory adherence.

Through these responsibilities, Quality Assurance (QA) functions as the backbone of the pharmaceutical quality system, ensuring that companies consistently comply with Good Manufacturing Practices (GMP), regulatory guidelines, and internal quality standards. By systematically controlling documentation, overseeing validation and change management, monitoring deviations and CAPA, and conducting audits and inspections, QA minimizes operational and regulatory risks that could compromise product quality or patient safety. Moreover, QA drives a culture of continuous improvement by analyzing quality trends, implementing preventive strategies, and promoting ongoing training and awareness. Collectively, these activities enhance process efficiency, strengthen regulatory readiness, and ensure the consistent delivery of safe, effective, and high-quality pharmaceutical products to the market.

4.2 Documentation and data integrity

Documentation is a cornerstone of QA, serving as evidence that processes have been followed correctly and consistently. Accurate, complete, and traceable records are essential for regulatory compliance and for building trust with stakeholders. Documentation includes batch records, SOPs, validation reports, audit findings, and training records, all of which must be maintained in a secure and accessible manner. Data integrity is equally critical, ensuring that information generated during manufacturing and testing is reliable and trustworthy. The principles of ALCOA+ (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available) guide best practices in data management. These principles ensure that data is properly attributed to individuals, recorded in real time, preserved in its original form, and accurate enough to withstand regulatory scrutiny [65-67].

Failures in documentation or data integrity can lead to severe regulatory consequences, including warning letters, product recalls, or suspension of manufacturing licenses. Therefore, QA departments invest heavily in training personnel, implementing electronic data management systems, and conducting routine audits to ensure compliance. In the era of digitalization, QA also plays a vital role in overseeing electronic records and ensuring that computerized systems meet regulatory requirements for security, traceability, and reliability. In summary, QA provides the systemic backbone of pharmaceutical manufacturing, ensuring that quality is not just tested but built into every process. Its responsibilities—from SOP development to CAPA implementation—are designed to prevent errors and maintain compliance with global regulatory standards. Documentation and data integrity further reinforce QA’s role as the guardian of transparency and reliability in pharmaceutical operations. Without QA, the industry would lack the preventive safeguards necessary to consistently deliver safe and effective medicines to patients.

5. Regulatory framework governing QC and QA

Pharmaceutical Quality Control (QC) and Quality Assurance (QA) activities are governed by a stringent regulatory framework designed to protect patient safety and ensure product reliability. At the global level, the World Health Organization (WHO) Good Manufacturing Practices (GMP) provide fundamental principles for pharmaceutical production, emphasizing hygiene, documentation, and validation of processes [65]. In the United States, the Food and Drug Administration (FDA) enforces compliance through 21 CFR Parts 210 and 211, which outline current Good Manufacturing Practices (cGMP) for manufacturing, processing, and packaging of drugs. Similarly, the European Union (EU) GMP Guidelines establish harmonized standards across member states, ensuring consistency in quality systems and facilitating international trade. Complementing these frameworks, the International Council for Harmonisation (ICH) Guidelines Q8–Q10 provide a scientific and risk-based approach to pharmaceutical development, quality risk management, and lifecycle quality systems. Regulatory agencies conduct routine and for-cause inspections to verify compliance, assess risk management practices, and ensure that companies maintain robust systems to safeguard patient health. Non-compliance can result in warning letters, product recalls, or suspension of manufacturing licenses, highlighting the critical importance of adhering to these regulations.

6. Integration of QC and QA in industrial operations

Effective pharmaceutical quality systems require close integration between QC and QA, as both functions complement each other in ensuring product quality. QC generates analytical data through testing of raw materials, intermediates, and finished products, while QA evaluates this data and authorizes decisions such as batch release. This interdependence ensures that only products meeting specifications are released to the market. Integration also facilitates cross-functional collaboration between manufacturing, QC, and QA teams, enabling rapid identification and resolution of deviations. By working together, QC and QA ensure timely batch release, regulatory compliance, and continuous improvement of processes. This synergy strengthens the overall culture of quality within organizations, ensuring that quality is not treated as a separate function but as a shared responsibility across departments.

7. Emerging trends in pharmaceutical QC/QA

Pharmaceutical quality systems are evolving rapidly with the adoption of advanced technologies and modern quality management approaches. One of the most significant trends is Quality by Design (QbD), which emphasizes designing quality into products and processes from the outset rather than relying solely on end-product testing. Process Analytical Technology (PAT) enables real-time monitoring of critical process parameters, allowing manufacturers to make immediate adjustments and reduce variability. Risk-based quality management is increasingly applied to prioritize resources and focus on areas with the highest potential impact on patient safety [48-54, 59-71]. The rise of digital quality management systems has transformed documentation and compliance, improving traceability and reducing human error. Furthermore, automation and data analytics are being integrated into QC laboratories and QA systems, enhancing efficiency, predictive capabilities, and decision-making. Collectively, these approaches improve process understanding, reduce quality risks, and align with regulatory expectations for continuous improvement.

Despite significant advancements, pharmaceutical companies continue to face challenges in implementing QC and QA systems effectively. Regulatory complexity across different regions creates difficulties for global manufacturers, who must comply with diverse standards and inspection practices. Ensuring data integrity in digital systems is another major challenge, as electronic records must meet strict requirements for security, traceability, and reliability. Managing deviations and product recalls requires robust systems and rapid response mechanisms, as failures can damage patient trust and company reputation. Additionally, the industry struggles with training and retaining skilled personnel, particularly in specialized areas such as analytical testing and regulatory compliance. Addressing these challenges requires strong leadership, continuous training, and fostering a culture of quality that prioritizes patient safety above all else. Companies that successfully overcome these barriers not only achieve regulatory compliance but also gain competitive advantages through operational excellence and enhanced credibility.

8. Future perspectives

The future of pharmaceutical Quality Control (QC) and Quality Assurance (QA) is expected to be shaped by predictive quality systems, real-time monitoring, and advanced digital technologies. Traditional quality systems have largely relied on retrospective testing and corrective actions; however, the industry is now moving toward predictive and preventive models that use data analytics, artificial intelligence (AI), and machine learning to anticipate potential deviations before they occur. Predictive quality systems will allow manufacturers to identify risks in real time, enabling proactive interventions that reduce variability and enhance product reliability.

Another key development is the adoption of real-time monitoring technologies, such as Process Analytical Technology (PAT) and continuous manufacturing systems. These innovations allow for ongoing assessment of critical quality attributes during production, ensuring that deviations are detected and corrected immediately rather than after batch completion. This shift toward continuous verification not only improves efficiency but also aligns with regulatory expectations for enhanced process understanding and control.

Artificial intelligence and automation will play a transformative role in the future of QC and QA. Automated systems can streamline routine testing, reduce human error, and accelerate batch release decisions. AI-driven platforms can analyze large datasets to uncover hidden trends, optimize manufacturing processes, and support decision-making in quality management. Furthermore, digital quality management systems (QMS) will integrate electronic documentation, audit trails, and compliance monitoring, strengthening data integrity and traceability.

On the regulatory front, continuous harmonization of global standards will further strengthen quality assurance practices. Organizations such as the ICH, WHO, FDA, and EMA are working toward unified frameworks that reduce regional disparities and facilitate international collaboration [59-71]. This harmonization will be particularly important as pharmaceutical supply chains become increasingly globalized. Innovation in regulatory science, including adaptive guidelines for emerging technologies, will also support the industry’s transition toward advanced quality systems.

Ultimately, the future of QC and QA lies in a synergistic blend of technology, regulatory evolution, and organizational culture. Companies that embrace predictive analytics, automation, and harmonized compliance frameworks will not only achieve higher efficiency but also reinforce their commitment to patient safety and ethical manufacturing.

9. Conclusion

Quality Control (QC) and Quality Assurance (QA) remain indispensable pillars of pharmaceutical manufacturing, ensuring that medicines consistently meet the highest standards of safety, efficacy, and quality. From the initial testing of raw materials to the final release of finished products, QC provides the analytical backbone that verifies compliance with specifications, while QA establishes the systemic safeguards that prevent errors and ensure consistency across operations. Together, they form a comprehensive quality framework that protects patients, supports regulatory compliance, and enhances industrial credibility. An integrated and proactive quality system not only safeguards patient health but also contributes to operational efficiency, risk reduction, and global competitiveness. By embedding quality into every stage of the product lifecycle, pharmaceutical companies can minimize variability, reduce recalls, and strengthen trust among healthcare providers and patients. Moreover, compliance with international regulatory frameworks such as GMP, FDA 21 CFR, and ICH guidelines ensures that companies maintain transparency, accountability, and resilience in an increasingly complex global market.

As the pharmaceutical industry continues to evolve with technological advancements and globalized supply chains, robust QC and QA systems will remain central to sustainable and ethical drug manufacturing. The integration of predictive quality models, real-time monitoring, and AI-driven analytics will redefine how companies approach quality, shifting from reactive to preventive strategies. In this context, QC and QA are not merely regulatory obligations but strategic imperatives that underpin innovation, patient safety, and long-term success.

Author Contributions: Conceptualisation, S.I.; software, S.I.; investigation, S.I.; writing—original draft preparation, S.I.; writing—review and editing, S.I.; visualisation, S.I.; supervision, S.I.; project administration, S.I. The author has read and agreed to the published version of the manuscript.

Funding: Not applicable.

Acknowledgments: We are grateful to the Department of Biotechnology, Faculty of Natural Science, Norwegian University of Science and Technology, Trondheim 7491, Norway for providing us all the facilities to carry out the entire work.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: All the related data are supplied in this work or have been referenced properly.

References

  1. Pathak SS, Tiwari A, Bhatt S, Shukla TP. Quality assurance and quality control in pharmaceutical industry. SCPM College of Pharmacy Journal. 2023. 
  2. Patil SD, Raut MK, Rathod NP. Quality control and quality assurance in pharmaceuticals. Int J Pharm Sci. 2023;1(11):91-102. 
  3. Henderson TJ. An introduction to pharmaceutical QA. Lab Manager. 2025. 
  4. World Health Organization. Good manufacturing practices for pharmaceutical products: main principles. WHO Technical Report Series. Geneva: WHO; 2020.
  5. U.S. Food and Drug Administration. Guidance for industry: Quality systems approach to pharmaceutical CGMP regulations. FDA; 2006.
  6. European Medicines Agency. Pharmaceutical quality system (ICH Q10). EMA; 2015.
  7. International Council for Harmonisation (ICH). Pharmaceutical development (ICH Q8) and Quality by Design principles. ICH; 2019.
  8. References (Vancouver Style)
  9. ICH Harmonised Tripartite Guideline Q10: Pharmaceutical Quality System. International Council for Harmonisation; 2008.
  10. ICH Harmonised Tripartite Guideline Q9: Quality Risk Management. International Council for Harmonisation; 2005.
  11. ICH Harmonised Tripartite Guideline Q8(R2): Pharmaceutical Development. International Council for Harmonisation; 2009.
  12. WHO. Good Manufacturing Practices for Pharmaceutical Products: Main Principles. WHO Technical Report Series; 2020.
  13. US FDA. Code of Federal Regulations Title 21, Parts 210–211. Washington, DC: FDA; 2021.
  14. European Medicines Agency. EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use. EMA; 2015.
  15. Yu LX, Woodcock J. FDA pharmaceutical quality system initiative. J Pharm Innov. 2010;5(1):1–6.
  16. Rathore AS, Winkle H. Quality by Design for biopharmaceuticals. Nat Biotechnol. 2009;27(1):26–34.
  17. Snyder LR, Kirkland JJ, Dolan JW. Introduction to Modern Liquid Chromatography. 3rd ed. Wiley; 2010.
  18. Reddy K, Rao P. Quality control in pharmaceutical industry. Int J Pharm Sci Rev Res. 2021;68(2):45–52.
  19. Sharma A, Gupta R. Quality assurance practices in pharmaceutical manufacturing. J Pharm Innov. 2020;9(3):112–118.
  20. MHRA. Guidance on Data Integrity. Medicines and Healthcare products Regulatory Agency; 2018.
  21. Patel H, Desai T. Integration of QC and QA in pharmaceutical operations. Pharm Technol. 2019;43(6):28–34.
  22. Singh P, Kaur J. Challenges in pharmaceutical quality systems. Asian J Pharm Clin Res. 2022;15(4):50–56.
  23. Yu LX. Pharmaceutical quality by design: product and process development, understanding, and control. Pharm Res. 2008;25(4):781–791.
  24. WHO. Quality assurance of pharmaceuticals: A compendium of guidelines and related materials. Geneva: WHO; 2018.
  25. FDA. Guidance for Industry: Quality Systems Approach to Pharmaceutical CGMP Regulations. FDA; 2006.
  26. EMA. Pharmaceutical Quality System (ICH Q10). EMA; 2015.
  27. Nasr M. Risk-based regulatory approaches in pharmaceutical quality. Pharm Technol. 2011;35(6):34–40.
  28. FDA. Guidance for Industry: PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. FDA; 2004.
  29. WHO. Annex 2: WHO good manufacturing practices for sterile pharmaceutical products. WHO Technical Report Series; 2019.
  30. FDA. Guidance for Industry: Process Validation: General Principles and Practices. FDA; 2011.
  31. EMA. Guideline on process validation for finished products. EMA; 2016.
  32. ICH Harmonised Guideline Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management. ICH; 2019.
  33. WHO. Annex 3: WHO guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems. WHO Technical Report Series; 2018.
  34. FDA. Guidance for Industry: Data Integrity and Compliance With Drug CGMP. FDA; 2018.
  35. EMA. Reflection paper on pharmaceutical development. EMA; 2013.
  36. WHO. Annex 5: Guidelines on validation. WHO Technical Report Series; 2016.
  37. FDA. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice. FDA; 2004.
  38. EMA. Guideline on setting specifications for new drug substances and products. EMA; 2014.
  39. WHO. Annex 7: Guidelines on good manufacturing practices for pharmaceutical products containing hazardous substances. WHO Technical Report Series; 2017.
  40. FDA. Guidance for Industry: Investigating Out-of-Specification Test Results for Pharmaceutical Production. FDA; 2006.
  41. EMA. Guideline on bioanalytical method validation. EMA; 2011.
  42. WHO. Annex 8: Guidelines on good manufacturing practices for pharmaceutical excipients. WHO Technical Report Series; 2015.
  43. FDA. Guidance for Industry: Quality Considerations for Continuous Manufacturing. FDA; 2019.
  44. EMA. Reflection paper on continuous manufacturing. EMA; 2018.
  45. WHO. Annex 9: Guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile products. WHO Technical Report Series; 2011.
  46. FDA. Guidance for Industry: Contract Manufacturing Arrangements for Drugs: Quality Agreements. FDA; 2016.
  47. EMA. Guideline on outsourced activities. EMA; 2017.
  48. WHO. Annex 10: Guidelines on good manufacturing practices for pharmaceutical products containing biological materials. WHO Technical Report Series; 2012.
  49. FDA. Guidance for Industry: Quality Metrics. FDA; 2015.
  50. EMA. Guideline on quality risk management. EMA; 2015.
  51. WHO. Annex 11: Guidelines on good manufacturing practices for pharmaceutical products containing active pharmaceutical ingredients. WHO Technical Report Series; 2014.
  52. FDA. Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity. FDA; 2015.
  53. EMA. Guideline on similar biological medicinal products. EMA; 2014.
  54. WHO. Annex 12: Guidelines on good manufacturing practices for pharmaceutical products containing radiopharmaceuticals. WHO Technical Report Series; 2013.
  55. FDA. Guidance for Industry: Quality Considerations for Generic Drugs. FDA; 2017.
  56. EMA. Guideline on generic medicinal products. EMA; 2016.
  57. WHO. Annex 13: Guidelines on good manufacturing practices for investigational pharmaceutical products. WHO Technical Report Series; 2016.
  58. FDA. Guidance for Industry: Investigational New Drug Applications. FDA; 2010.
  59. EMA. Guideline on clinical trial applications. EMA; 2015.
  60. WHO. Annex 14: Guidelines on good manufacturing practices for herbal medicines. WHO Technical Report Series; 2018.
  61. FDA. Guidance for Industry: Botanical Drug Development. FDA; 2016.
  62. EMA. Guideline on herbal medicinal products. EMA; 2017.
  63. WHO. Annex 15: Guidelines on good manufacturing practices for pharmaceutical products containing vaccines. WHO Technical Report Series; 2015.
  64. FDA. Guidance for Industry: Quality Considerations for Vaccines. FDA; 2018.
  65. EMA. Guideline on vaccine quality. EMA; 2019.
  66. WHO. Annex 16: Guidelines on good manufacturing practices for pharmaceutical products containing blood products. WHO Technical Report Series; 2014.
  67. FDA. Guidance for Industry: Blood and Blood Components Quality. FDA; 2015.
  68. EMA. Guideline on plasma-derived medicinal products. EMA; 2016.
  69. WHO. Annex 17: Guidelines on good manufacturing practices for pharmaceutical products containing biotechnology-derived products. WHO Technical Report Series; 2017.
  70. FDA. Guidance for Industry: Biotechnology Product Quality. FDA; 2019.
  71. EMA. Guideline on biotechnology-derived medicinal products. EMA; 2018.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of Global Journal of Basic Science and/or the editor(s). Global Journal of Basic Science and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. 

Copyright: © 2025 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Loading

Bibliography